1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > IMS Pharmaceutical Pricing & Reimbursement Concise Guide: UK

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Table Of Contents

IMS Pharmaceutical Pricing and Reimbursement Concise Guide: UK
UK ...1
HEALTHCARE SYSTEM..1
Facts and Figures ..1
Market Indicators2
Provision and Funding ...4
Separate Administration ..5
England5
Scotland, Wales and Northern Ireland 7
PRICING...7
Prescription Drugs..7
2014 PPRS..8
Statutory Drug Price Controls10
Rebates and Discounts .10
Generic Drugs ..11
Branded .11
Unbranded.11
Reimbursement Prices ..11
Hospital Drugs..11
Procurement ..11
Average Selling Prices ..11
OTC Drugs ...12
REIMBURSEMENT 12
Admission to Reimbursement ..12
England..12
Scotland.15
Wales.16
Northern Ireland.17
Patient Access Schemes...17
Early Access to Medicines.19
Negative List and Grey List ...19
Reimbursement Categories .20
Reimbursement Prices.20
Drug Tariff..20
Hospital Reimbursement..22
Formularies22
Funding..22
Changes in Reimbursement Status .23
England..23
Scotland.25
Wales.25
Northern Ireland.25
Changes in Reimbursement Prices .26
Price Increases..26
Price Modulation27
Flexible Pricing ..27
Overspending 28
Patient Access Schemes...28
Generics 28
Health Service Medicines Regulations ..29
Other DH Proposals ..30
PHARMACOECONOMICS.30
Pharmacoeconomic Requirements..30
England..31
Scotland.36
Wales.37
Northern Ireland.38
Proposed Reforms.38
PRICE BUILD UP ...39
Wholesalers .39
Margins ..39
Background39
Retail Pharmacies 40
Margins ..40
Dispensing Fees41
Pharmacy Clawback..41
Background42
Drug Classification.42
Dispensing Doctors ..43
Sales Tax .43
COST CONTAINMENT ..43
Industry Paybacks43
PPRS.43
Health Service Medicines Regulations ..44
Promotional Costs44
Promotional Expenditure ...44
Code of Conduct45
Advertising.45
Patient Co-payments45
Healthcare .45
Pharmaceuticals 46
Prescribing Controls.46
Prescribing Budgets ..46
Prescribing Incentive Schemes .46
Prescribing Restrictions.47
Frameworks ...47
Local Formularies ..47
Prescribing Guidelines...47
Prescribing Data and Monitoring ...48
E-prescribing..49
Prescribing Powers49
Generics...50
Rx-to-OTC Switches 50
Switching Process .50
Parallel Trade...51
FUTURE DEVELOPMENTS ..52
Outlook.52
EU Referendum.52
Impact of EU Withdrawal on the Pharmaceutical Sector ..52
NHS Funding .54
Reform of NICE Appraisal Process ...55
Statutory Drug Price Controls57
Maximum Prices 57
Price Disclosure.58
Pharmacy Funding 58
Accelerated Access Review ..59
NAMES and ADDRESSES 60

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025 Summary Hyperparathyroidism (HPT) is a common endocrinal disorder characterized by excessive plasma levels of parathyroid ...

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second ...

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025 Summary Hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market and Cardiovascular Disease Statistics in the US

  • March 2017
    30 pages
  • Therapy  

    Cardiovascular ...  

    Cholesterol  

  • United States  

View report >

Insulin Market and Diabetes Statistics in the US

  • March 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Diabetes Statistics

  • March 2017
    10 pages
  • Diabetes  

    Therapy  

View report >

Related Market Segments :

Therapy

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.